CRMD vs. TGTX
CRMD (CorMedix Inc.) and TGTX (TG Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, CRMD returned -1.91%/yr vs 21.61%/yr for TGTX. At a 0.20 correlation, their price movements are largely independent.
Performance
CRMD vs. TGTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRMD achieves a -24.85% return, which is significantly lower than TGTX's 66.12% return. Over the past 10 years, CRMD has underperformed TGTX with an annualized return of -1.91%, while TGTX has yielded a comparatively higher 21.61% annualized return.
CRMD
- 1D
- -2.46%
- 1M
- 16.53%
- YTD
- -24.85%
- 6M
- -23.93%
- 1Y
- -41.18%
- 3Y*
- 15.11%
- 5Y*
- 1.21%
- 10Y*
- -1.91%
TGTX
- 1D
- 3.06%
- 1M
- 16.11%
- YTD
- 66.12%
- 6M
- 57.96%
- 1Y
- 32.51%
- 3Y*
- 21.69%
- 5Y*
- 5.57%
- 10Y*
- 21.61%
CRMD vs. TGTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CRMD CorMedix Inc. | -24.85% | 43.58% | 115.43% | -10.90% | -7.25% | -38.76% | 2.06% | 12.87% | 158.00% | -67.32% |
TGTX TG Therapeutics, Inc. | 66.12% | -0.96% | 76.23% | 44.38% | -37.74% | -63.48% | 368.65% | 170.73% | -50.00% | 76.34% |
Correlation
The correlation between CRMD and TGTX is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.33 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since May 13, 2010 | 0.20 |
The correlation between CRMD and TGTX shifts across timeframes, from 0.20 (all time) to 0.33 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
CRMD:
$812.69M
TGTX:
$7.93B
CRMD:
$2.10
TGTX:
$2.87
CRMD:
4.16
TGTX:
17.23
CRMD:
1.88
TGTX:
11.37
CRMD:
1.86
TGTX:
13.59
CRMD:
$400.05M
TGTX:
$700.35M
CRMD:
$343.39M
TGTX:
$581.54M
CRMD:
$207.97M
TGTX:
$156.88M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRMD vs. TGTX — Risk / Return Rank
CRMD
TGTX
CRMD vs. TGTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CorMedix Inc. (CRMD) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRMD | TGTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.30 | ||
| Sortino ratioReturn per unit of downside risk | -1.84 | ||
| Omega ratioGain probability vs. loss probability | 0.92 | 1.16 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.66 | 1.00 | -1.66 |
| Martin ratioReturn relative to average drawdown | -0.97 | 1.81 | -2.78 |
Loading charts...
Drawdowns
CRMD vs. TGTX - Drawdown Comparison
The maximum CRMD drawdown since its inception was -98.28%, roughly equal to the maximum TGTX drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for CRMD and TGTX.
Loading charts...
Drawdown Indicators
| CRMD | TGTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.28% | -99.52% | +1.24% |
Max Drawdown (1Y)Largest decline over 1 year | -62.26% | -32.66% | -29.60% |
Max Drawdown (3Y)Largest decline over 3 years | -62.26% | -75.42% | +13.16% |
Max Drawdown (5Y)Largest decline over 5 years | -66.91% | -90.75% | +23.84% |
Max Drawdown (10Y)Largest decline over 10 years | -94.77% | -93.19% | -1.58% |
Current DrawdownCurrent decline from peak | -82.29% | -78.79% | -3.50% |
Average DrawdownAverage peak-to-trough decline | -77.55% | -91.43% | +13.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.56% | 18.04% | +24.52% |
Volatility
CRMD vs. TGTX - Volatility Comparison
The current volatility for CorMedix Inc. (CRMD) is 12.12%, while TG Therapeutics, Inc. (TGTX) has a volatility of 15.65%. This indicates that CRMD experiences smaller price fluctuations and is considered to be less risky than TGTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRMD | TGTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.12% | 15.65% | -3.53% |
Volatility (6M)Calculated over the trailing 6-month period | 51.58% | 34.28% | +17.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 68.31% | 47.22% | +21.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 77.11% | 87.77% | -10.66% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 91.70% | 86.88% | +4.82% |
Dividends
CRMD vs. TGTX - Dividend Comparison
Neither CRMD nor TGTX has paid dividends to shareholders.
Financials
CRMD vs. TGTX - Financials Comparison
This section allows you to compare key financial metrics between CorMedix Inc. and TG Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CRMD vs. TGTX - Profitability Comparison
CRMD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CorMedix Inc. reported a gross profit of 105.12M and revenue of 127.43M. Therefore, the gross margin over that period was 82.5%.
TGTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.
CRMD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CorMedix Inc. reported an operating income of 63.66M and revenue of 127.43M, resulting in an operating margin of 50.0%.
TGTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.
CRMD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CorMedix Inc. reported a net income of 38.60M and revenue of 127.43M, resulting in a net margin of 30.3%.
TGTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.
Frequently Asked Questions
CRMD and TGTX have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TGTX has higher volatility (15.65%) compared to CRMD (12.12%). In terms of maximum drawdown, CRMD dropped -98.28% vs TGTX's -99.52%.
TGTX currently has the higher Sharpe Ratio (0.69 vs -0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRMD and TGTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer